Progyny Inc.

4 days ago · zacks.com

Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

5 days ago · seekingalpha.com

Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.

13 days ago · zacks.com

The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

19 days ago · globenewswire.com

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.

27 days ago · defenseworld.net

Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating

1 month ago · gurufocus.com

On August 11, 2026, Progyny Inc (PGNY) shares fell by 4.6%, bringing the current price to $26.55. The stock has seen significant volatility, with a 52-week high

2 months ago · globenewswire.com

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.

2 months ago · marketbeat.com

Progyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.

2 months ago · seekingalpha.com

Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.